CellectisCMVLF 59 Days Payable is 675.86 as of Mar. 2026, which is 16% below its 10-year median of 809.28. GuruFocus rates CMVLF with a GF Score™ of 59/100 and a GF Value™ of $4.33 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 707 Biotechnology companies, Cellectis ranks better than 82.04% on this metric.
Cellectis's average Accounts Payable for the
three
months ended in Mar. 2026 was $17.18 Mil. Cellectis's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $2.32 Mil.
Hence, Cellectis's Days Payable for the
three
months ended in Mar. 2026 was 675.86.
The historical rank and industry rank for Cellectis's Days Payable or its related term are showing as below:
CMVLF'
s Days Payable Range Over the Past 10 Years
Min: 268.28 Med: 809.28 Max: 4613.72
Current: 625.39
During the past 13 years, Cellectis's highest Days Payable was 4613.72. The lowest was 268.28. And the median was 809.28.
CMVLF's Days Payable is ranked better than 82.04% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs CMVLF: 625.39
Cellectis's Days Payable
declined
from Mar. 2025 (812.26) to Mar. 2026 (675.86).
It may suggest that Cellectisaccelerated paying its suppliers.
Cellectis Days Payable Related Terms
Cellectis Days Payable Historical Data
* Premium members only.
The historical data trend for Cellectis's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMVLF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Cellectis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellectis Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cellectis's Days Payable distribution charts can be found below:
* The bar in red indicates where Cellectis's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cellectis's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectis (CMVLF) has a Days Payable of 675.86 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cellectis and its competitors. This is 16% below median its historical median of 809.28. Over the past decade, Cellectis' Days Payable has ranged from 268.28 to 4,613.72. According to the industry distribution chart, Cellectis ranks #127 out of 707 companies in the Biotechnology industry, placing it in the top 18%.
Is Cellectis' Days Payable too high?
Cellectis' current Days Payable of 675.86 is 16% below median its 10-year median of 809.28. Over the past 10 years, this metric has ranged from a low of 268.28 to a high of 4,613.72. The Biotechnology industry median Days Payable is 113.76. Cellectis' value of 675.86 is 494.1% above this industry median. Based on the distribution chart, Cellectis ranks #127 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cellectis has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cellectis' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cellectis ranks #127 out of 707 companies for Days Payable. This places Cellectis in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. Cellectis' value of 675.86 is 494.1% above this benchmark. Historically, Cellectis' own Days Payable has ranged from 268.28 to 4,613.72 over the past decade. While the company's 10-year median is 809.28 vs. the industry median of 113.76, Cellectis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellectis's current Days Payable of 675.86 is 494.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cellectis and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellectis's current Days Payable is 675.86, which is 16% below median its own 10-year median of 809.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectis stock overvalued right now?
Based on GuruFocus' analysis, Cellectis (CMVLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.33, compared to a current price of $3.47 — trading 19.9% below its estimated fair value. The current Days Payable is 675.86, which is 16% below median its 10-year median of 809.28 and 494.1% above the Biotechnology industry median of 113.76. Cellectis' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cellectis (CMVLF), the current Days Payable is 675.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cellectis (CMVLF) Overvalued in 2026?
Based on GuruFocus' analysis, Cellectis stock appears to be undervalued.
The current stock price of $3.47 is trading 19.9% below its estimated GF Value™ of $4.33.
GuruFocus considers Cellectis to be Modestly Undervalued.
Key valuation signals for CMVLF:
Days Payable: 675.86 (16% below median its 10-year median of 809.28)
GF Value™: $4.33 vs. price of $3.47 (19.9% below fair value)
Industry Position: 494.1% above the Biotechnology median (#127 of 707)
No single metric tells the full story. See the CMVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
59GF Score
Get the complete analysis for CMVLF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMVLF has been successfully added to your 
